Global Eosinophilic Esophagitis Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Eosinophilic Esophagitis Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn. Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

Market Overview:

The latest research study on the global Eosinophilic Esophagitis Drug market finds that the global Eosinophilic Esophagitis Drug market reached a value of USD 181.83 million in 2022. It’s expected that the market will achieve USD 305.51 million by 2028, exhibiting a CAGR of 9.03% during the forecast period.

The drug may have some side effects

The FDA currently has no drugs available to treat eosinophilic esophagitis. All drugs used in EoE prescriptions should be considered off-label and experimental. Currently topical steroids, such as fluticasone or budesonide, are the main drugs for the treatment of EoE. But for some patients, continued use of steroids by swallowing can cause side effects of Candida infection (yeast infection of the mouth and esophagus). In addition, some patients do not have obvious effects on steroid therapy, and they still need to rely on diet management to control their condition.

Strict regulatory policies in the pharmaceutical industry

The production of medicines must maintain high standards to ensure the strength of the active ingredients and the quality and purity of the final product. These standards ensure that safe and effective products are provided for patients. Therefore, most governments in the world have implemented regulations on pharmaceutical companies, and each country has strict regulations on the production and marketing of drugs. These regulations often extend the process of bringing new drugs to the market. However, because EoE is a rare chronic esophageal inflammatory disease, pharmaceutical companies can apply for orphan drug qualification. This is because the government encourages pharmaceutical companies to develop treatments for rare diseases. These incentives may include faster approval times and financial assistance.

Region Overview:

In 2022, the share of the Eosinophilic Esophagitis Drug market in North America stood at 43.25%.

Company Overview:

AstraZeneca is one of the major players operating in the Eosinophilic Esophagitis Drug market, holding a share of 32.59% in 2023.

AstraZeneca

AstraZeneca is a science-led global biopharmaceutical company dedicated to the discovery, development and commercialization of prescription drugs.

GSK

GlaxoSmithKline Plc is a healthcare company engaged in the research, development and production of drugs, vaccines and drugs.

Segmentation Overview:

By type, Budesonide segment accounted for the largest share of market in 2022.

Budesonide

Budesonide is a corticosteroid or steroid. Topical budesonide has a good effect on eosinophilic esophagitis. This treatment is called oral viscous budesonide (OVB).

Fluticasone

Fluticasone is a corticosteroid drug used to treat symptoms related to excessive immune responses caused by various diseases such as allergies and asthma. Fluticasone can safely and effectively induce remission in many patients with eosinophilic esophagitis (EoE). Generally, the drug is well tolerated. The main side effects may include hoarseness or sore throat, yeast infection in the esophagus (candida).

Application Overview:

The market's largest segment by application is the segment Hospitals, with a market share of 53.42% in 2022.

Key Companies in the global Eosinophilic Esophagitis Drug market covered in Chapter 3:

AstraZeneca
Dr. Falk Pharma
Teva
Bayer
GSK

In Chapter 4 and Chapter 14.2, on the basis of types, the Eosinophilic Esophagitis Drug market from 2018 to 2029 is primarily split into:

Budesonide
Fluticasone
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Eosinophilic Esophagitis Drug market from 2018 to 2029 covers:

Hospitals
Clinics
Drugstore

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)